For research use only. Not for therapeutic Use.
AGN 193109（Cat No.:I001549） is a retinoic acid analog that acts as a potent and specific antagonist of retinoic acid receptors (RARs). It effectively inhibits the activity of RARα, RARβ, and RARγ, with dissociation constant (Kd) values of 2 nM, 2 nM, and 3 nM, respectively. By antagonizing RARs, AGN 193109 interferes with the signaling pathways regulated by these receptors, which are involved in various biological processes. This compound shows potential for further exploration and development as a therapeutic agent targeting RAR-mediated pathways in conditions such as cancer, inflammation, and developmental disorders.
| Catalog Number | I001549 |
| CAS Number | 171746-21-7 |
| Synonyms | AGN193109;4-[2-[5,5-dimethyl-8-(4-methylphenyl)-6H-naphthalen-2-yl]ethynyl]benzoic acid |
| Molecular Formula | C28H24O2 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Storage | -20°C |
| IUPAC Name | 4-[2-[5,5-dimethyl-8-(4-methylphenyl)-6H-naphthalen-2-yl]ethynyl]benzoic acid |
| InChI | InChI=1S/C28H24O2/c1-19-4-11-22(12-5-19)24-16-17-28(2,3)26-15-10-21(18-25(24)26)7-6-20-8-13-23(14-9-20)27(29)30/h4-5,8-16,18H,17H2,1-3H3,(H,29,30) |
| InChIKey | NCEQLLNVRRTCKJ-UHFFFAOYSA-N |
| SMILES | CC1=CC=C(C=C1)C2=CCC(C3=C2C=C(C=C3)C#CC4=CC=C(C=C4)C(=O)O)(C)C |
| Reference | 1:J Biol Chem. 1996 May 24;271(21):12209-12. AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells.Agarwal C,Chandraratna RA,Johnson AT,Rorke EA,Eckert RL, PMID: 8647816 </br><span>Abstract:</span> Retinoids are important physiological agents that regulate epithelial cell differentiation and proliferation. The importance of these agents in regulating growth, development, and differentiation has led to a search for new retinoid agonists and antagonists. In the present manuscript we show that AGN193109, a retinoid analog, is an efficient antagonist of retinoid action in human cervical epithelial cells. Treatment of ECE16-1 cells with natural or synthetic retinoids reduces cytokeratin K5, K6, K14, K16, and K17 levels, increases cytokeratin K7, K8, and K19 levels, increases retinoic acid receptor-beta (RAR beta) mRNA levels, suppresses proliferation, and alters cell morphology. Co-treatment with AGN193109 prevents these responses. Half-maximal and maximal antagonism is observed at a molar ratio of AGN193109: retinoid agonist of 1:1 and 10:1, respectively. When administered alone AGN193109 has no agonist activity. Thus, AGN193109, which binds to RAR alpha, RAR beta, and RAR gamma with Kd values = 2,2, and 3 nm, respectively, but is unable to bind to the retinoid X receptors, is a highly active antagonist of retinoid action in ECE16-1 cells. |
